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Abstract
Background: We have demonstrated that the stromal cell-derived factor-1 (SDF-1; CXCL12)/
CXCR4 system is involved in the establishment of lymph node metastasis in oral squamous cell
carcinoma (SCC). Chemotherapy is a powerful tool for the treatment of oral cancer, including oral
SCC; however, the effects of chemotherapeutic agents on the expression of CXCR4 are unknown.
In this study, we examined the expression of CXCR4 associated with the chemotherapeutic agents
in oral cancer cells.
Results: The expression of CXCR4 was examined using 3 different chemotherapeutic agents; 5-
fluorouracil, cisplatin, and vesnarinone (3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2-
(1H)-quinolinone) in B88, a line of oral cancer cells that exhibits high levels of CXCR4 and lymph
node metastatic potential. Of the 3 chemotherapeutic agents that we examined, only vesnarinone
downregulated the expression of CXCR4 at the mRNA as well as the protein level. Vesnarinone
significantly inhibited lymph node metastasis in tumor-bearing nude mice. Moreover, vesnarinone
markedly inhibited 2.7-kb human CXCR4 promoter activity, and we identified the transcription
factor, Krüppel-like factor 2 (KLF2), as a novel vesnarinone-responsive molecule, which was bound
to the CXCR4 promoter at positions -300 to -167 relative to the transcription start site. The
forced-expression of KLF2 led to the downregulation of CXCR4 mRNA and impaired CXCR4
promoter activity. The use of siRNA against KLF2 led to an upregulation of CXCR4 mRNA.
Conclusion: These Results indicate that vesnarinone downregulates CXCR4 via the upregulation
of KLF2 in oral cancer.
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Background
Worldwide, oral cancer, excluding pharyngeal cancer, rep-
resents 2.65% of all human malignancies [1]. Most oral
cancer is histopathologically diagnosed as SCC. Oral can-
cers, including OSCC are characterized by a high degree of
local invasion and a high rate of metastases to the cervical
lymph nodes. In particular, it has been demonstrated that
lymph node metastasis directly affects the prognosis of
patients with OSCC as a results of extracapsular spread
and induces the secondary distant metastasis [2,3].
Lymph node metastasis is frequently detected upon the
first visit to a hospital, but it also appears during initial
treatments that include radiotherapy and chemotherapy.
Lymph node metastasis has been primarily treated by sur-
gical resection, although pre- or post-operative chemo-
therapy and/or pre- or post-operative radiotherapy have
been reported to be useful for achieving a favorable course
[4,5]. Despite the evidence accumulated to date, there is
no known molecular target for anti-metastatic therapy
against nodal involvement patients with oral cancer.
Chemokines are a large family of small (7–15 kDa), struc-
turally related, heparin-binding proteins that have been
identified as attractants of different types of blood leuko-
cytes to sites of infection and inflammation [6]. They are
produced locally in various tissues and act on leukocytes
via selective membrane-bound G protein-coupled recep-
tors, the two major subfamilies of which are CCR and
CXCR. Among these chemokines and their receptors, the
SDF-1 (also referred to as CXCL12)/CXCR4 system has
been shown to be involved in both lymph node and dis-
tant metastases of several types of cancer [7-12]. We have
also demonstrated that lymph node metastatic OSCC cells
specifically express functional CXCR4, and the SDF-1/
CXCR4 system is involved in lymph node metastatic proc-
esses in OSCC [13,14]. Moreover, we recently revealed
that the expression of CXCR4 in OSCC at the primary site
was significantly associated with lymph node metastasis,
mode of invasion, tumor recurrence, and patient progno-
sis [15]. Recently, we have demonstrated that, in cases of
oral SCC, the paracrine SDF-1/CXCR4 system potentiates
lymph node metastasis, but distant metastasis might
require the autocrine SDF-1/CXCR4 system [16].
Considering the importance of CXCR4 in a variety of can-
cers, attempts have been made to blockade this molecule
as a therapeutic target. For example, the administration of
CXCR4-neutralizing antibody into tumor-bearing mice by
Müller and colleagues inhibited lymph node and lung
metastasis in a breast cancer metastasis model [7]. Fur-
thermore, CXCR4 has been shown to function as a co-
receptor for T cell line-tropic HIV-1 entry [17]; and for this
reason, there has been considerable interest in the clinical
potential of CXCR4 inhibitors such as bicyclam
AMD3100 [18], horseshoe crab-derived peptide T22 [19],
and the non-peptide TAK-779 [20] for inhibiting HIV
infection. However, the clinical application of such inhib-
itors must be approached with caution, in light of the
importance of the CXCR4 pathway in normal lymphohe-
matopoiesis [21]. Moreover, for the effective treatment of
cancer, compounds with growth inhibitory effects as well
as anti-metastatic effects are desirable. Therefore, if con-
ventional chemotherapeutic agents that exert inhibitory
effects on CXCR4 are identified, it is expected that anti-
metastatic therapy could be performed more safely and
effectively. However, the molecular mechanism(s) of
diverse chemotherapeutic agents against CXCR4 expres-
sion are not yet fully understood. Thus, in this study, we
examined the transcriptional regulation of CXCR4 by
chemotherapeutic agents in an oral cancer cell line, B88,
which expresses high levels of CXCR4, and which exhibits
lymph node metastatic potential in vivo.
Methods
Reagents and materials
For in vitro experiments, vesnarinone (OPC-8212; Otsuka
Pharmaceutical Company, Tokyo, Japan) was dissolved in
DMSO at concentration of 10 mg/ml as the first stock
solution, and the first stock solution was diluted with the
complete culture medium [22]. For in vivo experiment,
vesnarinone was suspended in 0.5% CMC (Daiichi seiya-
kukogyo, Kyoto, Japan) [23]. 5-FU (Sigma, St. Louis, MO)
and CDDP (Sigma) was dissolved in DMSO at concentra-
tion of 1 mg/ml, and diluted with the complete culture
medium at 10 μg/ml. Several CXCR4 promoter luciferase
construct was kindly provided by Drs. Peter Staller and
Wilhelm Krek (Friedrich Miescher Institute for Biomedical
Research, Basel, Switzerland). KLF2 expression vectors
(pcDNA3-KLF2, pcDNA3-Δ KLF2, and pGEX-4T-1-KLF2)
were generous gifts from Drs. Sucharita Banerjee and
Mukesh K Jain (Cardiovascular Division, Brigham and
Women's Hospital, Boston, MA).
Mice
BALB/c nude mice were purchased from CLEA Japan
(Osaka, Japan). The mice were maintained under patho-
gen-free conditions and were handled in accordance with
the Guidelines for Animal Experimentation of Tokushima
University. The experiments were initiated when the mice
were 8 weeks of age and were performed as described pre-
viously [24]. The experimental chemotherapy by use of
vesnarinone was performed as described previously with
slight modification [23]. Briefly, B88 cells constitutively
expressing firefly luciferase (B88-luc) were orthotopically
inoculated into masseter muscle of nude mice. One week
later, the mice were treated by the daily oral administra-
tion of 0.5% CMC (5 ml/kg) for a vehicle or 0.2 ml of 10
mg/ml vesnarinone (50 mg/kg). The tumor volume wasMolecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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estimated by measuring tumor size and using the follow-
ing formula: tumor volume = 1/2 × L × W2, where L and
W represent the largest diameter, and the smallest diame-
ter, respectively. The presence or absence of lymph node
and distant metastases was confirmed by the H&E stain-
ing.
Cells and cell culture
High pulmonary metastases clone ACC-M was selected
from cell line ACC-2 that was derived from surgically
excised primary tumor tissue from a histologically diag-
nosed patient with adenoid cystic carcinoma of the palate
[25]. ACC-M and B88 cells [13] were maintained in RPMI-
1640 and DMEM, respectively, supplemented with 10%
fetal calf serum (FCS), 100 μg/ml streptomycin, and 100
U/ml penicillin in a humidified atmosphere of 95% air
and 5% CO2 at 37°C. ACC-M cell lines were supplied
friendly from Drs. Weiliu Qiu and Wantao Che (Labora-
tory of Tumor Biology, Ninth People's Hospital, Shanghai
Jiao Tong University, School of Stamotology).
Quantitative RT-PCR
After stimulation of the cells with or without chemother-
apeutic agents, the preparation of total RNA and reverse
transcription were performed as described previously
[15]. In quantitative PCR, CXCR4 and KLF2, CXCR7 or
GAPDH mRNA were detected with QuantiTect™ Gene
Expression Assays (Hs-CXCR4; Qiagen, Hilden, Ger-
many) and Taqman™ Gene Expression Assay (Applied
Biosystems, Foster City, CA), respectively. Gene-specific
products were measured continuously by an ABI PRISM
7000 Sequence Detection System (Applied Biosystems)
during 40 cycles. Experiments were performed at least
three times.
Flow cytometric analysis
Logarithmically growing oral cancer cells were trypsinized
and fixed in 4% (w/v) paraformaldehyde on ice for 10
min. The cells were washed and incubated with anti-
human CXCR4 mAb (dilution 1:100, 12G5; BioSource
International, Inc. Camarillo, CA) or mouse IgG isotype
control (SouthernBiotech, Birmingham, CA) for 30 min
at room temperature. After being washed twice with PBS,
the cells were incubated with PE-labeled goat anti-mouse
IgG (Serotec, Sapporo, Japan) for 30 min at room temper-
ature and analyzed with an EPICS flow cytometer (Coul-
ter, San Jose, CA).
In vitro cell migration assay
The in vitro migration of B88 cells was evaluated using the
Transwell (CORNING, Corning, NY) as described previ-
ously [13]. In some experiments, cells were incubated
with vesnarinone (50 μg/ml) or were transfected with
KLF2 expression vectors before the addition of cells in the
upper chamber.
Construction of CXCR4 promoter-luciferase reporter 
plasmids
Several truncated promoter constructs (Figure 1) were
generated by restriction digestion of pGL2-CXCR4 (-832/
+86) with KpnI and MluI for pGL2-CXCR4 (-300/+86),
with KpnI and SacII for pGL2-CXCR4 (-29/+86), or with
KpnI and XhoI for pGL2-CXCR4 (0). The digested frag-
ments were treated with T4 DNA polymerase (Takara Bio-
medicals, Kusatsu, Japan) and self-ligated with T4 DNA
ligase (Takara Biomedicals). pGL2-CXCR4 (-167/+86)
and pGL2-CXCR4 (-72/+86) were generated by PCR,
using CXCR4-UP (5'-GGGGTACCCAAACTTAGGAAAT-
GCCTCTGGGA-3') and CXCR4-DN1 (5'-GGGGTAC-
CAGCGGCGCATGCGCCGCGCTCGGAGCG-3'), and
CXCR4-UP and CXCR4-DN2 (5'-CCGCTCGAGCCTC-
CATGGTAACCGCTGGT-3'), respectively.
Transcriptional regulation of CXCR4 promoter by 
vesnarinone
B88 or ACC-M cells (5 × 105 cells/dish) were co-trans-
fected with 5 μg of CXCR4-luciferase reporter vectors and
0.5 μg of pcDNA3 (Invitrogen, Carlsbad, CA) by electro-
poration (140 V, 99 msec, 1 pulse), using ELECTRO
SQUARE PORATOR T820 (BTX Inc., San Diego, CA). After
transfection, stable transfectants were isolated and the
cells were treated with or without 50 μg/ml of vesnari-
none as indicated. Then, the cells were lysed with cell cul-
ture lysis reagent (Pikkagene, Toyo Ink, Tokyo, Japan),
and luciferase activity was measured by a Lumat LB9507
(BERTHOLD TECHNOLOGIES, Wildbad, Germany)
using a luciferase assay kit (Toyo Ink) according to the
manufacture's instruction. The luciferase activity was nor-
malized by protein quantitation. Each experiment was
repeated at least twice.
Inhibition of luciferase activity in the presence of vesnarinone Figure 1
Inhibition of luciferase activity in the presence of 
vesnarinone. Several CXCR4-luciferase constructs were 
transfected into B88 cells, which were treated with or with-
out vesnarinone for 48 h, and then luciferase activities were 
measured.Molecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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cDNA microarray
Total RNA for cDNA microarray analysis was extracted
from B88 cells treated with or without vesnarinone for 48
h. cDNA microarray was performed and analyzed in
Hokkaido System Science (Sapporo, Japan) using a
human 1A Oligo Array (Agilent Technologies, Palo Alto,
CA).
Chromatin immunoprecipitation (ChIP) assay
B88 cells were treated with or without vesnarinone for 48
h, or were transfected with pcDNA3 or pcDNA3-KLF2.
ChIP assay was performed by using a ChIP assay kit
according to the manufacture's instruction (upstate, Lake
Placid, NY). Briefly, equal aliquots of isolated chromatin
DNA were subjected to immunoprecipitation with a rab-
bit KLF2 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA). The DNA fragments associated with specific immu-
noprecipitates were purified and used as templates for the
PCR in order to amplify the CXCR4 promoter sequences
containing a CACCC/KLF binding site (-401 to -142). The
primers used were 5'-CAGCAAGTCACTCCC-3' and 5'-
GGAGAGGTGCGCGGC-3'.
Electrophoretic mobility-shift assay (EMSA)
Biotinylated double stranded oligonucleotides of CXCR4
promoter sequence at positions -204 to -175 containing
the CACCC site (5'-ACTCACTACCGACCACCCG-
CAAACAGCAGG-3') or a mutated CACCC site (5'-ACT-
CACTACCGACTGTTTGCAAACAGCAGG-3') were
synthesized in Hokkaido System Science. After transfor-
mation of glutathione S-transferase (GST) or GST-KLF2
plasmid vectors into BL21 (DE3) competent cells (Merck,
Darmstadt, Germany), recombinant proteins were
extracted, and were purified with glutathione sepharose
column (Amersham Pharmacia Biotech.). EMSA was per-
formed using LightShift Chemiluminescent EMSA Kit
(Pierce, Rockford, IL) according to the manufacture's
instruction.
siRNA assay
siRNA against KLF2 was synthesized in B-Bridge interna-
tional (Mountain View, CA). siRNA cocktails against KLF2
or negative control siRNA (B-Bridge International) were
transfected into B88 cells, using Lipofectamine 2000 rea-
gent (Invitrogen) at the final concentration of 20 nM or
200 nM. After 48-h incubation, total RNA was extracted
and quantitative RT-PCR was performed.
Statistical analysis
Statistical differences between the means for the different
groups were evaluated with StatView 4.5 (Abacus Con-
cepts, Berkeley, CA) using one-way ANOVA, with the level
of significance at P < 0.05. All experiments were repeated
two to three times, and similar Results were obtained.
Results
Expression of CXCR4 induced by the chemotherapeutic 
agents
In complete medium or DMSO, the expression of CXCR4
mRNA was transiently downregulated after the medium
was changed, but mRNA expression was gradually upreg-
ulated and recovered to the basal level at 24 h (Figure 2a).
Initially, two conventional cytocidal chemotherapeutic
agents for treating oral cancer, namely 5-FU and CDDP,
were assessed, but the expression of CXCR4 mRNA was
not altered with these treatments. Therefore, we tested the
effect of a novel cytostatic chemotherapeutic agent, vesna-
rinone [22]. It was revealed that vesnarinone markedly
Downregulation of CXCR4 by vesnarinone Figure 2
Downregulation of CXCR4 by vesnarinone. (a) 
CXCR4 mRNA was examined by quantitative PCR in B88 
cells treated with chemotherapeutic agents (CDDP, 5-FU, or 
vesnarinone) or vehicle DMSO. (b) B88 cells treated with or 
without chemotherapeutic agents were incubated with or 
without anti-CXCR4 monoclonal antibody. Then the cells 
were incubated with PE-labeled goat anti-mouse IgG and ana-
lyzed by flow cytometry in order to determine the expres-
sion of CXCR4 protein. The white zones show the cells 
treated with vesnarinone stained by mouse IgG isotype con-
trol. The black zones show cells treated with vesnarinone, 
and gray zones show the cells treated with DMSO (upper), 5-
FU (middle), or CDDP (lower), respectively. The black zones 
and gray zones were stained by anti-CXCR4 monoclonal 
antibody. (c) Vesnarinone downregulates CXCR4 mRNA and 
upregulates KLF2 mRNA in a time-dependent manner in 
ACC-M cells. ACC-M cells were treated with vesnarinone 
and quantitative RT-PCR was performed.Molecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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downregulated the expression of CXCR4 mRNA and pro-
tein, as compared to the effects of DMSO, 5-FU, or CDDP
in B88 cells (Figure 2a and 2b). Downregulation of
CXCR4 mRNA by treatment with vesnarinone was also
detected in oral cancer cells, ACC-M, in a time dependent
manner (Figure 2c). Moreover, we also found the reduced
expression of CXCR4 protein by the treatment with vesna-
rinone, as compared to the effects of 5-FU and CDDP
both in ACC-M cells and in Hela cells (Additional File 1).
Next, we examined the effect of vesnarinone on the
expression of CXCR7, which was recently identified as a
chemokine receptor that binds chemokines CXCL11 and
SDF-1 [26]. However, analyses of cDNA microarray and
quantitative RT-PCR revealed that vesnarinone was not
found to change the expression of CXCR7 (data not
shown).
Effects of vesnarinone on the migration and lymph node 
metastasis of B88 cells
In order to investigate the functional role played by
CXCR4 downregulation with vesnarinone, an in vitro
migration assay was performed. SDF-1 was found to
enhance the migration of B88 cells, which was in contrast
significantly inhibited by treatment with vesnarinone
(Figure 3a). In order to further clarify the role of vesnari-
none on lymph node metastasis, experimental chemo-
therapy was carried out. Vesnarinone significantly
inhibited the size and weight of the metastatic lymph
nodes in the orthotopic inoculation of B88 cells to nude
mice (Figure 3b, c and 3d). Furthermore, when treated
with vesnarinone, B88 cells constitutively expressing fire-
fly luciferase showed significantly impaired luciferase
activity in the metastatic lymph nodes (Figure 3e).
Transcriptional regulation of the CXCR4 gene by 
vesnarinone
Since vesnarinone appeared to inhibit the lymph node
metastasis by downregulating CXCR4, we investigated in
greater detail the transcriptional regulation of CXCR4 by
vesnarinone. A luciferase reporter vector driven by the 2.7-
kb CXCR4 promoter region was transfected into B88 cells,
and the stable transfectants were isolated. As shown in
Additional File 2a, luciferase activities of the CXCR4 pro-
moter, when treated with vesnarinone, were significantly
lower than those of the promoter treated with DMSO
vehicle alone. In order to further clarify the transcriptional
regulatory region activated by vesnarinone in the CXCR4
promoter, we isolated several B88-transfectants with trun-
cated CXCR4 promoter-luciferase constructs, and in those
treated with vesnarinone, we observed an inhibition of
luciferase activity driven downstream of the truncated
CXCR4 promoters up to position -300 from the transcrip-
tion starting site (Additional File 2b and 2c). However, the
luciferase activity driven upstream of position -167 was
not significantly impaired by treatment with vesnarinone
(Additional File 2d, e, f and Figure 1). These results indi-
cate that the vesnarinone-regulatory element on the
CXCR4 promoter was located at positions -300 to -167
from the transcription starting site (Figure 1).
Identification of vesnarinone-regulatory element on the 
CXCR4 promoter region
Positions -300 to -167 contained several canonical tran-
scription factor binding sites such as E-box, NF-κB,
Inhibition of migration and lymph node metastasis by vesnari- none in B88 cells Figure 3
Inhibition of migration and lymph node metastasis by 
vesnarinone in B88 cells. (a) B88 cells were seeded on the 
upper membrane in the presence or absence of SDF-1α in 
the lower compartment, and in the presence of vesnarinone 
in the upper compartment. After 24 h, cells attached to the 
lower surface of the membrane were subjected to H&E 
staining and were counted. The bars show the SD of tripli-
cate samples. Data are representative of three separate 
experiments with similar results. *, Not significant as deter-
mined by one-way ANOVA. (b, c, d and e) B88-luc cells (2 × 
106) were inoculated into the masseter muscle of nude mice, 
which were treated with or without vesnarinone and were 
sacrificed at day 14 (d) or day 28 (b, c, d and e). Extirpated 
lymph nodes (b), H&E staining of the lymph nodes (c) (bar, 
50 μm), and the weight of lymph nodes (d) are shown. *, Sig-
nificant as determined by one-way ANOVA (vs. controls, P < 
0.01). (e) Lymph nodes were lysed and then luciferase activ-
ity was measured. *, Significant as determined by one-way 
ANOVA (vs. controls, P < 0.01).Molecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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nuclear factor of activated T cells, and Krüppel-like factor
(KLF). Therefore, we performed a microarray analysis to
identify the vesnarinone-regulatory element on the
CXCR4 promoter. Numerous molecules were upregulated
or downregulated by treatment with vesnarinone, but the
gene related to the vesnarinone-regulatory element and
that with the highest upregulation detected was KLF2. To
verify whether or not KLF2 binds to vesnarinone-regula-
tory element, we next performed a ChIP assay. After treat-
ment with vesnarinone, KLF2 preferentially bound to
vesnarinone-regulatory element (Figure 4a). Moreover,
forced expression of KLF2 also led to binding to vesnari-
none-regulatory element in the absence of vesnarinone
stimulation, which indicated that KLF2 might regulate the
expression of CXCR4 (Figure 4a). Next, we carried out an
EMSA in order to confirm the binding of KLF2 to vesnari-
none-regulatory element. Recombinant KLF2 effectively
bound to the CXCR4 promoter sequence at positions -204
to -175 containing the CACCC site; however, the binding
was not inhibited by the addition of excess volume of
mutant probe (Figure 4b).
Effects of KLF2 on the downregulation of CXCR4
Next, we confirmed the upregulation of KLF2 by treat-
ment with vesnarinone. Vesnarinone was found to upreg-
ulate KLF2 mRNA in a time-dependent manner both in
B88 cells (Figure 5a) and in ACC-M (Figure 2c) cells.
Therefore, we investigated the role played by KLF2 in the
downregulation of CXCR4. Forced expression of KLF2
downregulated CXCR4 mRNA, but forced expression of
ΔKLF2, with a deleted DNA binding domain, did not lead
to such downregulation (Figure 5b). Moreover, forced
expression of KLF2 also attenuated the luciferase activity
driven by the CXCR4 promoter (-300/+76) both in B88
cells (Figure 5c) and in ACC-M cells (Additional File 3).
Next, we examined the functional effects of KLF2 on the
cell migration induced by SDF-1. In B88 cells, the migra-
tion induced by SDF-1 was significantly inhibited by the
forced expression of KLF2, but this was not observed in
the case of either pcDNA3 or ΔKLF2 (Figure 5d).
Effects of silencing KLF2 on the expression of CXCR4
Since the overexpression of KLF2 induced the downregu-
lation of CXCR4, we next attempted to examine the
expression of CXCR4 using KLF2 knock-down and siRNA
approaches. The introduction of the siRNA against KLF2
exhibited a 50% decrease in the KLF2 mRNA levels (Figure
6a), which in turn markedly upregulated CXCR4 mRNA
(Figure 6b).
Discussion
Vesnarinone, a synthetic quinolinone derivative with ino-
tropic effects, was originally developed to treat cardiac
KLF2 binding to the CXCR4 promoter via a CACCC site Figure 4
KLF2 binding to the CXCR4 promoter via a CACCC 
site. (a) ChIP assay. B88 cells were treated with or without 
vesnarinone for 48 h, or were transfected with pcDNA3 or 
pcDNA3-KLF2. Equal aliquots of isolated chromatin DNA 
were subjected to immunoprecipitation with rabbit KLF2 
antibody, and the DNA fragments associated with specific 
immunoprecipitates were purified and used as templates for 
the PCR in order to amplify the CXCR4 promoter 
sequences containing the CACCC/KLF2 binding site (-401 to 
-142). (b) EMSA. Ten micrograms of recombinant GST or 
GST-KLF2 protein were incubated in the biotinylated 
CXCR4 promoter containing the CACCC site with or with-
out an excess volume (200 fold) of non-labeled wild type 
probe (Cold WT Pr) or that of non-labeled mutated probe 
(Cold MU Pr).Molecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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failure [27] and has been clinically used for the treatment
of patients with chronic congestive heart failure [28].
Vesnarinone was not developed as a targeted agent; how-
ever, recent studies have revealed that vesnarinone is a
unique anti-proliferation [22,23], differentiation-induc-
ing [29] and apoptosis inducing [30,31] agent against sev-
eral human malignancies, including leukemia and several
types of solid tumors. Furthermore, clinical studies have
shown that vesnarinone potentiates the effects of conven-
tional cytotoxic chemotherapy and radiotherapy [32-34].
We have been studying the molecular mechanism of the
growth inhibitory effects of vesnarinone against the head
and neck cancer cells, and we demonstrated that vesnari-
none induces the expression of various kinds of genes
such as p21waf1 [35] and transforming growth factor β
stimulated clone (tsc)-22 [22]. A previous phase study
revealed that two partial responses against metastatic
lesions in a patient with metastatic breast cancer involving
lymph nodes, liver, and bone, and in a patient with met-
Induction of KLF2 mRNA by vesnarinone and downregula- tion of CXCR4 by KLF2 Figure 5
Induction of KLF2 mRNA by vesnarinone and down-
regulation of CXCR4 by KLF2. (a) Vesnarinone upregu-
lates KLF2 mRNA in a time-dependent manner. B88 cells 
were treated with vesnarinone and quantitative RT-PCR was 
performed. (b) Forced expression of KLF2 downregulates 
CXCR4 mRNA. pcDNA3, KLF2 or ΔKLF2 expression vec-
tors were transfected into B88 cells. After 48 h, quantitative 
RT-PCR was performed. (c) Forced expression of KLF2 
impaired CXCR4 promoter activity. Stable transfectants of 
CXCR4 promoter-luciferase construct (-300/+86) were 
transfected with pcDNA3, KLF2, or ΔKLF2 expression vec-
tors, and then luciferase activity was measured at the indi-
cated time points. *, Significant as determined by one-way 
ANOVA (vs. pcDNA3, P < 0.01). (d) Forced expression of 
KLF2 impaired cell migration induced by SDF-1. B88 cells 
that had been transiently transfected with KLF2 expression 
vectors were seeded on the upper membrane in the pres-
ence or absence of SDF-1α in the lower compartment. After 
24 h, cells attached to the lower surface of the membrane 
were stained by H&E and were counted. *, P < 0.05 (one-way 
ANOVA). The bars show the SD of triplicate samples. Data 
are representative of three separate experiments with simi-
lar results.
Enhanced CXCR4 expression by siRNA against KLF2 Figure 6
Enhanced CXCR4 expression by siRNA against KLF2. 
siRNA cocktails against KLF2 were transfected into B88 cells. 
After 48 h, quantitative RT-PCR against KLF2 (a) and CXCR4 
(b) was performed. Data are representative of two separate 
experiments with similar results.Molecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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astatic non-small-cell lung cancer involving the brain and
lymph node, when the patients were treated with vesnari-
none and gemcitabine [34]. These clinical observations
suggested the anti-metastatic activity of vesnarinone;
however, the molecular mechanism of the anti-metastatic
action of vesnarinone remained unclarified in those stud-
ies. Vesnarinone was shown to exhibit anti-proliferating
effects at a dose of 200 mg/kg against a human adenoid
squamous carcinoma-forming cell line grown in nude
mice [23]. In order to specifically investigate the anti-met-
astatic effects of vesnarinone, we administrated a lower
dose of vesnarinone (50 mg/kg) to tumor-bearing nude
mice. As expected, vesnarinone did not inhibit tumor size
in the masseter muscle (data not shown), but it did
inhibit the lymph node metastasis. These results indicated
that although vesnarinone specifically inhibits lymph
node metastasis, this does not occur by inhibition of
lymph node cell growth.
In the present study, we demonstrated the novel transcrip-
tional regulation of CXCR4 via the transcription factor
KLF2 in vesnarinone-treated oral cancer cells. It has been
shown that the expression of CXCR4 is transcriptionally
upregulated by several transcription factors such as c-Myc
[36], NF-κB [37] and hypoxia inducible factor (HIF) [38],
and is downregulated by Yin-Yang 1 [36]. In addition,
cytokine signaling induced by granulocyte colony-stimu-
lating factor [39], interferon gamma [40], and tumor
necrosis factor-alpha [41] have also been reported to reg-
ulate CXCR4 expression. Among these transcription fac-
tors and cytokine signaling, vesnarinone-regulatory
element located in the region between -300 and -167 from
the transcriptional starting site contained one canonical
NF-κB binding site. On the other hand, Manna and co-
workers reported that vesnarinone suppresses the TNF-
induced activation of NF-κB [42]. Thus, we initially
expected to find that NF-κB is a vesnarinone-inducible
transcriptional regulator for CXCR4. However, our site-
directed mutagenesis study showed that vesnarinone did
alter promoter activity in samples with either a mutated
NF-κB site or that of samples with a wild-type NF-κB site
(data not shown]. Moreover, our microarray analysis
revealed that treatment with vesnarinone did not alter NF-
κB subunit p50 and p65 mRNA levels. Thus, we con-
cluded that NF-κB is not a vesnarinone-inducible CXCR4
regulator.
KLF2 [i.e., lung Krüppel-like factor (LKLF)], was originally
identified through the use of the zinc finger domain of
erythroid Krüppel-like factor (ELKF) as a hybridization
probe; and KLF2 is expressed in a limited number of tis-
sues, with the predominant expression seen in the lungs
and spleen [43]. KLF2 is required to program the quies-
cent state of T cells via the downregulation of c-Myc [44].
Moreover, it has been demonstrated that KLF2 regulates
diverse biological activities, such as adipogenesis [45],
inflammation [46], cell growth [47], apoptosis [48], tum-
origenesis [49], and angiogenesis [50]. In these processes,
KLF2 upregulates p21waf1 [47] and cytosolic phospholi-
pase A2 alpha [49], and downregulates several types of
molecules, including peroxisome proliferator-activated
receptor-gamma [44], vascular cell adhesion molecule-1
[46], E-selectin [45], WEE1 [48], and vascular endothelial
growth factor receptor 2 [50]. KLF2 is grouped with KLF1
and KLF4, which are characterized by amino-terminal
acidic activation domains, inhibitory regions adjacent to
the zinc fingers, and conserved nuclear localization sig-
nals, and which function both as activators as well as
repressors [51]. However, abundant evidence suggested
that KLF2 dominantly functions as a repressor. In the
present study, KLF2 was also found to negatively regulate
CXCR4 expression, most likely via the binding of a canon-
ical CACCC motif. Since other KLF families are able to rec-
ognize this motif, CXCR4 may be downregulated by other
KLF families. However, of the 13 members of the KLF fam-
ily examined in the present microarray analysis (data not
shown), only KLF2 mRNA was upregulated by 48-h treat-
ment with vesnarinone. Thus, as regards the regulation of
CXCR4 expression by vesnarinone, it is expected that
KLF2 is the most important regulator among the member
of KLF family that putatively binds to this CACCC motif.
In the present study, the mechanism of transcriptional
upregulation of KLF2 by vesnarinone was still unclear. We
have previously demonstrated that vesnarinone directly
activates p21waf1 gene promoter via Sp1 sites in a human
salivary gland cancer cell line [34]. Since the 5'-flanking
region of the KLF2 gene manifests typical features of GC-
rich promoter with multiple transcription factor Sp1
binding sites [51], KLF2 might be also upregulated by
vesnarinone via the activation of Sp1.
CXCR4 functions as a coreceptor for T cell line-tropic HIV-
1 entry. Previously, vesnarinone was found to inhibit the
replication of HIV-1 in a peripheral blood lymphocyte
model via the inhibition of cytokine production [52].
Although vesnarinone was not developed as a targeted
agent against CXCR4, it may have other targets against the
metastasis of oral cancer. However, this effect might have
been the result of the impaired expression of CXCR4 in
peripheral blood lymphocytes due to treatment with
vesnarinone. The findings of the present study suggest
that vesnarinone might be useful as an anti-metastatic
agent for patients with CXCR4-related oral cancer. Moreo-
ver, our clinical observations suggest that whereas vesna-
rinone does not exert dramatic anti-tumor effects, it does
induce tumor differentiation and dormancy, effects previ-
ously shown to prolong the lives of patients with headMolecular Cancer 2009, 8:62 http://www.molecular-cancer.com/content/8/1/62
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and neck cancers [32,33]. Due to agranulocytosis and
mild anti-tumor effects, care must be taken to administer
vesnarinone as the sole agent as a first-line therapy to
patients with OSCC. However, a combination of vesnari-
none with conventional chemotherapy or radiotherapy
might be used as a novel second- or third-line anti-meta-
static intervention in patients with CXCR4-related OSCC.
Conclusion
Our results indicated that vesnarinone downregulates
CXCR4 expression via the upregulation of KLF2 in oral
cancer.
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